Efficient Ablation of Genes in Human Hematopoietic Stem and Effector Cells using CRISPR/Cas9  by Mandal, Pankaj K. et al.
Short Article
Efficient Ablation of Genes in Human Hematopoietic
Stem and Effector Cells using CRISPR/Cas9
Graphical Abstract
Highlights
Efficient ablation of B2M and CCR5 in human hematopoietic
cells using CRISPR/Cas9
CRISPR/Cas9 CCR5-deleted CD34+ HSPCs retain multilineage
engraftment potential
Minimal off-target mutational events in CD34+ HSPCs after
CRISPR/Cas9 treatment
Authors
Pankaj K. Mandal, Leonardo







Genome editing has the potential to revo-
lutionize cell-based gene therapy. In this
study, Mandal et al. developed ap-
proaches for using CRISPR/Cas9 in hu-
man CD34+ HSPCs that yielded high on-
target with minimal off-target mutagen-
esis. These results indicate that
CRISPR/Cas9 could broadly enable
gene and cell-based therapies of blood.
Accession Numbers
PRJNA264619
Mandal et al., 2014, Cell Stem Cell 15, 643–652




Efficient Ablation of Genes in Human Hematopoietic
Stem and Effector Cells using CRISPR/Cas9
Pankaj K. Mandal,1,2,14 Leonardo M.R. Ferreira,1,3,14 Ryan Collins,4 Torsten B. Meissner,1 Christian L. Boutwell,5
Max Friesen,1 Vladimir Vrbanac,5,6 Brian S. Garrison,1,2,7 Alexei Stortchevoi,4 David Bryder,8 Kiran Musunuru,1,9,10,11
Harrison Brand,4 Andrew M. Tager,5,6 Todd M. Allen,5 Michael E. Talkowski,4,11,12 Derrick J. Rossi,1,2,7,9,*
and Chad A. Cowan1,9,11,13,*
1Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA
2Program in Cellular and Molecular Medicine, Division of Hematology/Oncology, Boston Children’s Hospital, Boston, MA 02116, USA
3Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA 02138, USA
4Molecular Neurogenetics Unit, Psychiatric and Neurodevelopmental Genetics Unit, Center for Human Genetic Research,
Massachusetts General Hospital, Boston, MA 02114, USA
5Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA
6Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital and Harvard Medical School, Charlestown,
MA 02129, USA
7Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA
8Institution for Experimental Medical Research, Immunology section, Lund University, 221 84, Lund, Sweden
9Harvard Stem Cell Institute, Cambridge, MA 02138, USA
10Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston, MA 02115, USA
11Broad Institute, Cambridge, MA 02142, USA
12Department of Neurology, Harvard Medical School, Boston, MA 02115, USA
13Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
14Co-first authors
*Correspondence: derrick.rossi@childrens.harvard.edu (D.J.R.), chad_cowan@harvard.edu (C.A.C.)
http://dx.doi.org/10.1016/j.stem.2014.10.004
SUMMARY
Genome editing via CRISPR/Cas9 has rapidly
become the tool of choice by virtue of its efficacy
and ease of use. However, CRISPR/Cas9-mediated
genome editing in clinically relevant human somatic
cells remains untested. Here, we report CRISPR/
Cas9 targeting of two clinically relevant genes,
B2M and CCR5, in primary human CD4+ T cells and
CD34+ hematopoietic stem and progenitor cells
(HSPCs). Use of single RNA guides led to highly effi-
cient mutagenesis in HSPCs but not in T cells. A dual
guide approach improved gene deletion efficacy in
both cell types. HSPCs that had undergone genome
editing with CRISPR/Cas9 retained multilineage
potential. We examined predicted on- and off-target
mutations via target capture sequencing in HSPCs
and observed low levels of off-target mutagenesis
at only one site. These results demonstrate that
CRISPR/Cas9 can efficiently ablate genes in HSPCs
with minimal off-target mutagenesis, which could
have broad applicability for hematopoietic cell-
based therapy.
INTRODUCTION
The hematopoietic system is at the forefront of cell-based gene
therapies due to the fact that the cells can be readily obtained,
manipulated, and reintroduced into patients. The development
of genome editing methodologies such as zinc finger nucleases
(ZFNs) and transcription activator-like effector nucleases
(TALENs) (Urnov et al., 2010);(Joung and Sander, 2013; Scharen-
berg et al., 2013) have enabled site-specific gene repair or
ablation and raised the possibility of treating a broad range
of diseases at the genetic level (Pan et al., 2013). Despite
much promise, limitations associated with these technologies,
including low targeting efficacy and de novo engineering of pro-
teins for each target, have precluded wide-spread adoption
of these technologies for therapeutic use (Silva et al., 2011).
The recent emergence of the clustered, regularly interspaced,
palindromic repeats (CRISPR) system for gene editing has
the potential to overcome these limitations (Jinek et al., 2012).
The CRISPR technology utilizes a fixed nuclease, often the
CRISPR-associated protein 9 (Cas9) from Streptococcus pyo-
genes, in combination with a short guide RNA (gRNA) to target
the nuclease to a specific DNA sequence (Cong et al., 2013;
Jinek et al., 2012, 2013; Mali et al., 2013). CRISPR/Cas9 relies
on simple base-pairing rules between the target DNA and the en-
gineered gRNA rather than protein-DNA interactions required by
ZFNs and TALENs (Gaj et al., 2013; Wei et al., 2013). As a result,
the CRISPR/Cas9 system has proven extremely simple and flex-
ible. Perhaps most important, this system has achieved highly
efficacious alteration of the genome in a number of cell types
and organisms (Ding et al., 2013; Hwang et al., 2013; Niu et al.,
2014; Wang et al., 2013; Wei et al., 2013).
Given the importance of the hematopoietic system in cell-
based gene therapies, we tested theCRISPR/Cas9 system in pri-
mary human CD4+ T cells and CD34+ hematopoietic stem and
progenitor cells (HSPCs) targeting two clinically relevant genes,
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beta-2 microglobulin (B2M) and chemokine receptor 5 (CCR5).
B2M encodes the accessory chain of major histocompatibility
complex (MHC) class I molecules and is required for their surface
expression (Bjorkman et al., 1987; Zijlstra et al., 1990). Deletion of
B2M is a well-established strategy to ablate MHC class I surface
expression (Riolobos et al., 2013) and could be used to generate
hypoimmunogenic cells for transplantation and adoptive immu-
notherapy. CCR5 is the main coreceptor used by CCR5-tropic
strains of HIV-1 (Trkola et al., 1996) and a validated target for
gene ablation, asmutations resulting in loss of protein expression
or haploinsufficiency protect against HIV infection (Catano et al.,
2011; Hu¨tter et al., 2009; Martinson et al., 1997; Samson et al.,
1996). Moreover, transplantation of CCR5 homozygous mutant
HSPCs provides long-term protection against HIV rebound
even after discontinuation of antiretroviral therapy (Allers et al.,
2011; Hu¨tter et al., 2009). Several attempts have been made to
target CCR5 in T cells (Perez et al., 2008; Tebas et al., 2014)
and HSPCs (Holt et al., 2010; Schleifman et al., 2011), though
the efficiency of gene targeting was not sufficient to protect
against viral recrudescence (Tebas et al., 2014). Recently,
CCR5 has been targeted using CRISPR/Cas9 in cell lines (Cho
et al., 2013) and iPS cells (Ye et al., 2014). However, CRISPR/
Cas9 gene editing in primary human hematopoietic cells remains
untested. Here we report that use of CRISPR/Cas9 with single
gRNAs led to highly efficient CCR5 ablation in CD34+ HSPCs
but not B2M in CD4+ T cells. Employing a dual gRNA approach
improved gene deletion efficacy in both cell types with biallelic
inactivation frequencies reaching 34% for B2M in CD4+ T cells
and 42% for CCR5 in CD34+ HSPCs. Importantly, CRISPR/
Cas9CCR5-editedCD34+HSPCs retainedmultilineage potential
in vitro and in vivo upon xenotransplantation. Deep target capture
sequencing of predicted on- andoff-target sites inCD34+HSPCs
revealed highly efficacious on-target mutagenesis and exceed-
ingly low off-target mutagenesis.
RESULTS
We designed gRNAs to target Cas9 to the B2M gene (Figure 1A).
Each guide was first tested for the ability to direct site-specific
mutations in HEK293T cells. Using flow cytometry we measured
the efficiency of each gRNA to direct Cas9-mediated ablation of
B2M surface expression 72 hr posttransfection (Figure 1B). We
observed that B2M was abrogated in 7% (±1.02 SEM, n = 3)
to 48% (±1.80 SEM, n = 3) of HEK293T cells depending upon
the gRNA utilized (Figure 1C; Figure S1A available online). Similar
results were observed using the Surveyor assay, with gRNA-
specific mutation frequencies of 0%–26% in HEK293T cells
(Figure S1B). We also designed gRNAs to target Cas9 to the
CCR5 gene (Figure 1D). Upon introducing these into K562 cells,
we measured targeting efficacy using the Surveyor assay and
observed mutation frequencies ranging from 22%–40% (Fig-
ure 1E). Variation in the efficiency with which a specific gRNA
directed Cas9-mediated ablation was observed, even between
gRNAs targeting the same exon or nearly overlapping sites (Fig-
ures 1A–1E) indicating that on-target efficiency of site-directed
mutation is highly gRNA dependent, as previously noted (Hsu
et al., 2013).
Next, we tested selected single gRNAs in CD4+ T cells and
CD34+ HSPCs. Surprisingly, gRNAs that were highly efficacious
at targeting B2M in HEK293T cells exhibited lower targeting
efficiencies in primary CD4+ T cells ranging from 1.4% (±0.2
SEM, n = 6) to 4.7% (±0.9 SEM, n = 6) ablation ofB2M expression
(Figures 1F, S1C, and S1D) or 3%–11% using the Surveyor
assay (Figures S1B and S1E). For instance, crB2M_13 exhibited
more than 10-fold reduced efficacy in CD4+ T cells (4.7% ±
0.9%) as compared to HEK293T cells (48.0% ± 1.8%) (Figures
1F and S1C). Interestingly, single gRNAs targeting CCR5
showed comparable mutation frequencies in CD34+ HSPCs as
observed in K562 cells (Figures 1E and 1G). To explore this
further, we performed direct Sanger sequencing of several
hundred colonies derived from HSPC clones targeted with
crCCR5_A or crCCR5_B from two donors and observed very
high mutation frequencies in all cases (Figure 1H). As only cells
expressing Cas9 were analyzed, it is unlikely that differences in
on-targetmutation efficiencywere due to differential transfection
efficiencies, although we cannot rule out differential transfection
of individual guides, but rather may reflect intrinsic properties of
certain primary hematopoietic cell types.
We reasoned that using two gRNAs directed against the same
locus might generate predictable mutations (deletions) more
frequently than that achieved by error-prone non-homologous
end joining, which represents the predominant DNA double
strand break repair pathway in HSPCs (Beerman et al., 2014).
Indeed, this approach has previously been utilized for ZFNs,
TALENs, and the CRISPR/Cas9 system to achieve predictable
deletions (Bauer et al., 2013; Canver et al., 2014; Gupta et al.,
2013; Lee et al., 2010; Wang et al., 2014; Zhou et al., 2014).
Six dual gRNA combinations targeting B2M with DNA sequence
lengths between their predicted Cas9 cleavage sites ranging
from 81 to 2,261 nt were introduced in CD4+ T cells together
with Cas9 (Figure 2A). We observed a trend of improved target-
ing efficacy for most of the tested gRNA pairs and greatly
improved efficacy for one gRNA pair (crB2M_13+8), which re-
sulted in 18.0% (±8.35 SEM, n = 3) ablation of B2M surface
expression (Figures 2B, 2C, and S2A). B2M ablation led to a
concomitant reduction of MHC class I cell surface expression
(Figure S2B). We further interrogated mutation frequency at a
clonal level via single-cell quantitative PCR, which revealed
28.2% (n = 301 cells analyzed) of CD4+ T cells were homozygous
null for B2M (Figure S2C). Upon Sanger sequencing across the
predicted Cas9 cutting sites, we observed deletion of the inter-
vening sequence (Figure S2D).
We next applied the dual guide strategy to primary CD34+
HSPCs by introducing three gRNA pairs along with Cas9 (Fig-
ure 2D). Sorted CD34+ HSPCs expressing Cas9 were plated
into methylcellulose and emergent clonal colonies were picked
2 weeks postplating for analysis. Individual colonies were
analyzed by PCR to quantify the deletion efficacy of CCR5
(Figures 2D and 2E). Remarkably, although variation in CCR5
ablation was noted among different donors and gRNA pairs,
we consistently observed high monoallelic and biallelic inactiva-
tion of CCR5 in all cases (Figures 2E and S2E). For example, one
dual gRNA combination (crCCR5_D+Q) generated biallelic
CCR5 deletion in CD34+ HSPCs at a rate of 26.8% (±7.1 SEM)
across four donors (Figures 2E and S2E). It should be noted,
however, that the mutation rates determined by this PCR strat-
egy underestimate actual mutation frequency, since small inser-
tions or deletions (InDels) are not detected by this approach. A
Cell Stem Cell
CRISPR/Cas9 Gene Ablation in Hematopoietic Cells
644 Cell Stem Cell 15, 643–652, November 6, 2014 ª2014 Elsevier Inc.
Figure 1. Targeting Clinically Relevant Loci in Human Cells Using CRISPR/Cas9
(A) Schematic of gRNAs targeting B2M.
(B) Histogram of B2M surface expression in HEK293T cells.
(C) B2M deletion efficiency with various gRNAs in HEK293T cells; n = 3 (mean ± SEM).
(D) Schematic of gRNAs targeting CCR5. Orange and green arrows represent primer pairs used to amplify the region for analysis.
(E) Surveyor assay of each gRNA targeting CCR5 in K562 cells. Percentage InDels is indicated under each guide.
(F) B2M deletion efficiency of selected gRNAs in primary CD4+ T cells in comparison to 293T cells; n = 6 (mean ± SEM).
(G) Surveyor assay of crCCR5_A and crCCR5_B targeting CCR5 in K562 cells and HSPCs.
(H) Clonal deletion efficiency of crCCR5_A and crCCR5_B targeting of CCR5 in HSPCs (n = 2) as determined by Sanger sequencing. (Note: crB2M_14 is not
depicted in [A] schematic, as it is located 20 kb downstream of coding sequence.). See also Figure S1.
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similar dual gRNA approach targeting CCR5 (crCCR5_A+B) in
CD4+ T cells resulted in a biallelic inactivation rate of 8.8% at
the single-cell level (n = 363) (Figure S2F). Again, after Sanger
sequencing, we noted excision of the DNA between the Cas9
cleavage sites (Figure S2G). Taken together, these data demon-
strate that highly efficacious ablation of clinically relevant genes
Figure 2. A Dual gRNA Approach for CRISPR/Cas9 Genome Editing in Primary Human Hematopoietic Stem and Effector Cells
(A) Schematic of dual gRNA approach for targeting theB2M locus. gRNA pairs are in red. The offset in base pairs between Cas9 sites for each gRNA combination
(right panel).
(B) B2M deletion efficiency in CD4+ T cells for six dual gRNA combinations (n = 3; mean ± SEM).
(C) FACS plots showing loss of B2M expression of either crB2M_13 or crB2M_8 alone or in combination in primary CD4+ T cells.
(D) Schematic of dual gRNA approach for targeting CCR5. gRNA pairs are shown in red. Orange and green arrowheads represent the primer pair used to amplify
the region. The offset between the Cas9 sites of each gRNA pair (right panel).
(E) Gel electrophoresis image of CD34+ HSPCs-derived clones targeted with crCCR5_D+Q analyzed by PCR. Note the deletion of the 205 bp region between the
two gRNA cutting sites (top panel; WT: wild-type; DCCR5: deleted; green *: WT; orange *: heterozygote; and red *: null clone). Clonal deletion efficiency for three
dual gRNA combinations targeting CCR5 in CD34+ HSPCs (n = 4; % mean ± SEM; bottom panel). See also Figure S2.
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can be achieved in primary hematopoietic CD4+ T cells and
CD34+ HSPCs using a dual gRNA strategy.
In order to determine whether CD34+ HSPCs that had under-
gone genome editing with CRISPR/Cas9 retained their potential
to differentiate into effector cells, we performed in vitro and
in vivo differentiation assays. Toward this, CCR5-edited CD34+
HSPCs were plated in methylcellulose and clonal colonies
that emerged 2 weeks postplating were counted and scored
for contribution to granulocyte, macrophage, erythrocyte, and
megakaryocyte lineages. Comparable colony numbers and col-
ony types were observed regardless of whether single, dual, or
no gRNAs were used demonstrating that CD34+ HSPC colony
forming potential was not impacted byCRISPR/Cas9 (Figure 3A),
despite the high CCR5 mutation frequencies observed in these
experiments (Figures 1H and 2E).
We next tested the in vivo reconstitution potential of HSPCs
following CRISPR/Cas9 targeting of CCR5 by xenotransplanta-
tion of control (Cas9-only), and CCR5-edited (Cas9 + crCCR5
D+Q) CD34+ HSPCs into NOD-PrkdcScid-IL2rgnull (NSG) recipi-
ents.Recipientswere sacrificedat 12weeksposttransplantation,
Figure 3. CCR5-Edited CD34+ HSPCs Retain Multilineage Potential
(A–C) (A) Representative pictures of colonies formed in methylcellulose CFC assay (left panel) with quantified data on colony number and types are presented
(right panel). Representative FACS plot showing human hematopoietic cell (hCD45+) engraftment andmultilineage reconstitution at 12 weeks posttransplantation
in the bone marrow (B) and spleen (C) of NSG recipient mice.
(D) PCR results confirmed predicted deletion of targeted region at CCR5 locus in human hematopoietic cells sorted from NSG mice transplanted with CRISPR/
Cas9-treated HSPCs. Human peripheral blood mononuclear cells (PBMCs) from healthy donor taken as control. (WT: wild-type; DCCR5: deleted.)
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Figure 4. Targeted Capture and Extremely Deep Sequencing of On-Target and Predicted Off-Target Sites in CD34+ HSPCs
(A) Schematic of targeted capture deep sequencing of on-target and predicted off-target sites (red bar); probe sets are indicated in blue. A 500 bp region flanking
the site (in yellow) was included for detection of structural rearrangements (i.e., translocations).
(B) Plots showing sequencing depth coverage at both on-target (left panel) and off-target (right panel) sites, achieving a coverage exceeding 3,0003 for all
on-target sites. Decrease in sequencing depth at the on-target sites in dual-gRNA libraries is marked by arrow, supporting predicted deletions (bottom left;
i = 35 bp, ii = 205 bp, iii = 205 bp).
(legend continued on next page)
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and human hematopoietic cell engraftment (hCD45+) was exam-
ined in the bone marrow, revealing CD19+ lymphoid cells and
CD11b+ myeloid cells (Figure 3B). Human CD45+ hematopoietic
cells were also found in the spleens of transplanted mice (Fig-
ure 3C). PCR analysis on DNA isolated from sorted human
CD45+ hematopoietic cells from reconstituted mice demon-
strated that CCR5-edited cells (DCCR5) robustly contributed to
humanhematopoietic cell chimerism (Figure 3D). Taken together,
these results demonstrate that CRISPR/Cas9 CCR5-edited
CD34+ HSPCs retained multilineage potential in vitro and in vivo.
CRISPR/Cas9 has been shown to generate off-target muta-
tions depending upon experimental setting and cell type (Cho
et al., 2014; Cradick et al., 2013; Fu et al., 2013; Fu et al.,
2014; Hruscha et al., 2013; Lin et al., 2014). To examine this,
we performed target capture sequencing of CD34+ HSPCs
subjected to CRISPR/Cas9 CCR5 editing. These experiments
captured each gRNA target site (n = 5) and predicted off-target
sites (n = 126) with expanded capture intervals of 500 bp flanking
each site to ensure accurate detection of any genetic lesion
occurring at or near the selected sites (Figure 4A; Table S1).
We have previously shown this approach can identify structural
variations, such as translocations and inversions, in proximity
to the capture site (Talkowski et al., 2011). Sorted CD34+ HSPCs
treated with Cas9 alone or in combination with multiple single or
dual gRNA combinations were sequenced to a mean target
coverage of 3,390X across each 23 bp gRNA sequence and
PAM (Figure 4B). Analysis of these data revealed highly effica-
cious on-target mutagenesis with a diverse array of mutated
sequence variants observed in both single and dual gRNA treat-
ments (Figure 4C). As expected, we detected small InDels of up
to 10 bp in addition to single nucleotide substitutions at the pre-
dicted target sites in single gRNA conditions. Strikingly, in each
dual gRNA experiment, no fewer than 15 alternate mutant alleles
were observed at either one of the gRNA sites (Tables S2–S4).
Notably, the sequencing depth of our analysis permitted estima-
tion of mutation frequency for each particular variant, including
mutations that were observed in only a few hundredths of a
percent of the sample sequenced (Table S5). Predicted deletions
(i.e., deletions between the two Cas9 target sites) were the
most common mutations observed, while small InDels were
also frequent (Figure 4C). Interestingly, for two combinations,
crCCR5_A+B and crCCR5_D+Q, we also observed inversions
between the predicted Cas9 cleavage sites. The most effica-
cious combination crCCR5_D+Q led to mutations in approxi-
mately 48% of the captured sequence reads.
We next examined the capture sequence reads at predicted
off-target sites in the genome (Table S1). An N-fold enrichment
analysis was performed, wherein we compared the total number
of non-reference sequencing reads at each predicted off-target
site in gRNA-treated and control (Cas9 only) samples. This anal-
ysis generated a ratio where 1.0 indicates an equivalent number
of nonreference sequence reads in both treated and control
samples, values less than 1.0 indicate fewer non-reference reads
in treated samples, and values greater than 1.0 indicate a greater
number of non-reference reads in treated samples (Figure 4D).
This analysis found that the mean enrichment of mutations at
off-target sites in all the gRNA-treated samples compared to
control closely conformed to the null hypothesis (i.e., 0.99-fold
enrichment compared to controls), indicating that off-target mu-
tation events were extremely rare. Indeed, statistical evaluation
of all captured off-target sites yielded a single site (1/126;
0.6%, Figure 4D) in the sample treated with crCCR5_B alone
that passed multiple test correction for a statistically significant
enrichment for off-target InDels versus controls (p % 7.6 3
1011) (Table S5). When we scrutinized the sequencing reads
from this site, which was located in the highly homologous
CCR2 gene (Figure S3A), we found that all sequence variants
(36 out of 5,963 total reads) were one or two base InDels, (Fig-
ure S3B). Of note, the other sample in which crCCR5_B was
used (in combination with crCCR5_A) only 13 out of 5,339 reads
supported mutation; however, these events did not meet statis-
tical significance above controls (Figure S3B; Table S5). Thus,
off-target mutagenesis was exceedingly rare and, moreover,
the use of two gRNAs in combination did not increase the very
low incidence of off-target mutagenesis. We also performed
analyses for structural variation at all sites, and though we
could readily detect on-target inversions in crCCR5_A+B and
crCCR5_D+Q treatments, there was no evidence for inversion
or translocation at any off-target sites. These data indicate that
on-target mutagenesis efficiency was very high and further that
off-target mutagenesis was extremely infrequent for both single
and dual gRNA treatments.
DISCUSSION
In this study we utilized the CRISPR/Cas9 system in human pri-
mary CD4+ T cells and CD34+ HSPCs to target two clinically rele-
vant genes B2M and CCR5. Surprisingly, the activity of the
CRISPR/Cas9 systemwas remarkably variable in different human
cell types, with the same gRNA exhibiting highly efficacious on
target mutagenic activity in HEK293T cells but little activity in
CD4+ T cells. In contrast, the targeting efficacy in K562 cells and
CD34+ HSPCs was comparable. Moreover, consistent with previ-
ous reports (Hsuetal., 2013),weobserved that theefficiencyof the
CRISPR/Cas9 system was gRNA specific, as even gRNAs with
partially overlapping sequences displayed significantly different
targeting efficiencies. Further, a dual gRNA approach yielded
increased gene ablation efficacy in both CD4+ T cells and CD34+
HSPCs, leading to predicted deletions at the targeted loci.
The lack of CRISPR/Cas9 activity observed in T cells, espe-
cially with single gRNAs, may be due to a number of factors,
including inefficient plasmid DNA delivery, the innate immune
(C) Precise estimation of on-target mutation allele frequencies by capture sequencing. Notably, the rate of mutation exceeds previous estimates by PCR of
predictable deletions, as smaller InDels and inversions also occur at appreciable frequencies.
(D) Estimation of mutation frequencies at predicted off-target sites. (*One off-target site was statistically different from controls following correction for multiple
comparisons; p% 7.63 1011.) N-fold enrichment is determined based on the ratio of non-reference reads in treated libraries compared to untreated library and
represents the average of all off-target sites for a given experiment. Enrichment of 1 is equivalent to untreated control. **For reference to on-target enrichments,
on-target combined represents the proportion of non-reference reads (including single and dual gRNA treatments using a given gRNA) to total reads at on-target
sites in treatment compared to control. See also Tables S1, S2, S3, S4, and S5.
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response of T cells to foreign nucleic acid (Monroe et al., 2014),
and/or active DNA repair machinery. Given the efficacy of the
CRISPR/Cas9 system in a wide variety of cell types and species
both in vitro and in vivo (Sander and Joung, 2014), the lack of ac-
tivity observed in T cells is likely the exception and not the rule.
Nonetheless, our results highlight that CRISPR/Cas9 targeting
efficacy can differ between cell lines and primary cells. Ulti-
mately, further studies will be necessary to determine how vari-
able the activity of CRISPR/Cas9 is in different primary human
cell types.
Our mutational analysis revealed highly efficacious mutagen-
esis of on-target sites in CD34+ HSPCs. Single gRNAs generated
a range ofmutations with the vastmajority comprised of small In-
Dels. In contrast, dual gRNA combinations largely led to pre-
dicted deletions, though a diverse array of mutations including
InDels and even inversions were detected. Importantly, we
only identified one statistically significant off-target site in the
highly homologous CCR2 gene, which occurred in one out of
six experimental settings (gRNA crCCR5_B alone). Sequence
analysis of crCCR5_B in comparison to the identified off-target
site in CCR2 indicated that it perfectly matched in the seed re-
gion and contained three sequence mismatches at the 50 end
of the gRNA sequence. These data are consistent with studies
showing that mismatches in the 50 end of the gRNA are tolerated
by Cas9 (Lin et al., 2014; Wu et al., 2014). Our data support the
idea that judicious guide design is critical for minimizing off-
target mutations. Of note, our very deep sequencing analysis
enabled detection of the lone off-target event, whereas analysis
performed at lower sequencing depth—such as 50X coverage
used in previous studies (Smith et al., 2014; Suzuki et al., 2014;
Veres et al., 2014)—would have been unable to detect this event.
Overall, our analysis of CRISPR/Cas9 mutational activity in
CD34+ HSPCs revealed very high on-target mutation rates and
extremely low incidence of off-target mutagenesis.
The ability to direct efficient and predictable deletions using
dual gRNAs opens the possibility of using this strategy to target
noncoding regions in the genome such as enhancers and si-
lencers that control expression of disease-relevant genes. For
example, recent studies have identified regulatory regions that
control expression of fetal hemoglobin (Bauer et al., 2013), which
if deleted increase fetal globin expression in cells otherwise
restricted to expressing adult b-globin (Bauer et al., 2013; Xu
et al., 2011). Targeted deletion of such regions in CD34+ HSPCs
followed by transplantation into patients may provide a durable
therapy for the treatment of b-hemoglobinopathies such as
sickle cell anemia and b-thalassemia (Xu et al., 2011). Overall,
our data demonstrate that CRISPR/Cas9 can be used to ablate
genes of clinical significance in CD4+ T cells and CD34+ HSPCs
with an efficiency that is therapeutically meaningful for a number
of clinical settings, such as the treatment of HIV. Our demon-
stration that CRISPR/Cas9-targeted CD34+ HSPCs retain multi-
lineage potential in vitro and in vivo, combined with very high
on-target and minimal off target mutation rates, suggests that
CRISPR/Cas9 could have broad applicability enabling gene
and cell-based therapies of the blood.
EXPERIMENTAL PROCEDURES
Animal experiments were done following institutional guidelines.
Molecular Biology
All guideswere designed using the online optimized design tool at http://crispr.
mit.edu. gRNA and primer sequences are enlisted in supplemental data.
Transfection of Cells
Human primary CD4+ T cells and CD34+ HSPCs were transfected with Cas9-
2A-GFP and gRNA encoding plasmids using respective Amaxa Nucleofector
kits using cell-specific Nucleofector program with Nucleofector II device.
Surveyor Assay
Amplicons spanning the different targeted regions were PCR amplified using
the Phusion polymerase and HF Buffer (New England Biolabs), and CEL assay
was carried out using the Surveyor Mutation detection kit (Transgenomic) as
per manufacturer’s instructions.
In Vivo Transplantation of CD34+ HSPCs
A total of 75,000 sorted CD34+ HSPCs expressing Cas9 alone (control group,
n = 2) or Cas9 with crCCR5_D+Q gRNAs (experimental group, n = 5) were
transplanted in to NSG recipient mice. At 12 weeks posttransplantation, all
mice were euthanized, and blood, bone marrow, and spleen samples were
taken for characterization of human hematopoietic cell chimerism. Human
CD45+ cells were sorted for DNA isolation and analysis of CCR5 deletion.
Off-Target Prediction and Capture Sequencing
Each guide RNA target site (n = 5) and predicted off-target sites (n = 126) was
selected for capture sequencing (Table S1) using the Agilent SureSelectXT
Target Enrichment System. Capture Sequencing was performed as described
earlier (Talkowski et al., 2011).
For details on experimental procedures, see Supplemental Information.
ACCESSION NUMBERS
All raw reads from capture sequencing are available at NCBI Bioproject,
accession number PRJNA264619.
SUPPLEMENTAL INFORMATION
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